136 related articles for article (PubMed ID: 30885980)
1. PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.
Cox OT; Edmunds SJ; Simon-Keller K; Li B; Moran B; Buckley NE; Bustamante-Garrido M; Healy N; O'Flanagan CH; Gallagher WM; Kennedy RD; Bernards R; Caldas C; Chin SF; Marx A; O'Connor R
Cancer Res; 2019 May; 79(10):2619-2633. PubMed ID: 30885980
[TBL] [Abstract][Full Text] [Related]
2. Essential function for PDLIM2 in cell polarization in three-dimensional cultures by feedback regulation of the β1-integrin-RhoA signaling axis.
Deevi RK; Cox OT; O'Connor R
Neoplasia; 2014 May; 16(5):422-31. PubMed ID: 24863845
[TBL] [Abstract][Full Text] [Related]
3. YAP and β-Catenin Cooperate to Drive Oncogenesis in Basal Breast Cancer.
Quinn HM; Vogel R; Popp O; Mertins P; Lan L; Messerschmidt C; Landshammer A; Lisek K; Château-Joubert S; Marangoni E; Koren E; Fuchs Y; Birchmeier W
Cancer Res; 2021 Apr; 81(8):2116-2127. PubMed ID: 33574090
[TBL] [Abstract][Full Text] [Related]
4. Sequestration of PDLIM2 in the cytoplasm of monocytic/macrophage cells is associated with adhesion and increased nuclear activity of NF-kappaB.
Healy NC; O'Connor R
J Leukoc Biol; 2009 Mar; 85(3):481-90. PubMed ID: 19052146
[TBL] [Abstract][Full Text] [Related]
5. PDLIM2: Signaling pathways and functions in cancer suppression and host immunity.
Guo ZS; Qu Z
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188630. PubMed ID: 34571051
[TBL] [Abstract][Full Text] [Related]
6. PDLIM2 prevents the malignant phenotype of hepatocellular carcinoma cells by negatively regulating β-catenin.
Jiang X; Chu Z; Cao Y; Tang Y; Shi Y; Shi X
Cancer Gene Ther; 2021 Nov; 28(10-11):1113-1124. PubMed ID: 33398035
[TBL] [Abstract][Full Text] [Related]
7. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
8. The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
El Ayachi I; Fatima I; Wend P; Alva-Ornelas JA; Runke S; Kuenzinger WL; Silva J; Silva W; Gray JK; Lehr S; Barch HC; Krutilina RI; White AC; Cardiff R; Yee LD; Yang L; O'Regan RM; Lowry WE; Seagroves TN; Seewaldt V; Krum SA; Miranda-Carboni GA
Cancer Res; 2019 Mar; 79(5):982-993. PubMed ID: 30563890
[TBL] [Abstract][Full Text] [Related]
9. PDLIM2 regulates transcription factor activity in epithelial-to-mesenchymal transition via the COP9 signalosome.
Bowe RA; Cox OT; Ayllón V; Tresse E; Healy NC; Edmunds SJ; Huigsloot M; O'Connor R
Mol Biol Cell; 2014 Jan; 25(1):184-95. PubMed ID: 24196835
[TBL] [Abstract][Full Text] [Related]
10. PDLIM2 acts as a cancer suppressor gene in non-small cell lung cancer via the down regulation of NF-κB signaling.
Shi H; Ji Y; Li W; Zhong Y; Ming Z
Mol Cell Probes; 2020 Oct; 53():101628. PubMed ID: 32621848
[TBL] [Abstract][Full Text] [Related]
11. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
Chen X; Yang M; Yin J; Li P; Zeng S; Zheng G; He Z; Liu H; Wang Q; Zhang F; Chen D
Cell Commun Signal; 2022 Jun; 20(1):92. PubMed ID: 35715860
[TBL] [Abstract][Full Text] [Related]
13. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
Shen H; Yan W; Yuan J; Wang Z; Wang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
[TBL] [Abstract][Full Text] [Related]
14. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
15. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
16. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
[TBL] [Abstract][Full Text] [Related]
17. Integrin α9 depletion promotes β-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis.
Wang Z; Li Y; Xiao Y; Lin HP; Yang P; Humphries B; Gao T; Yang C
Int J Cancer; 2019 Nov; 145(10):2767-2780. PubMed ID: 31008533
[TBL] [Abstract][Full Text] [Related]
18. PDLIM2 is highly expressed in Breast Cancer tumour-associated macrophages and is required for M2 macrophage polarization.
Cox OT; O'Sullivan N; Tresse E; Ward S; Buckley N; O'Connor R
Front Oncol; 2022; 12():1028959. PubMed ID: 36531051
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer.
Qu Z; Fu J; Yan P; Hu J; Cheng SY; Xiao G
J Biol Chem; 2010 Apr; 285(16):11786-92. PubMed ID: 20185823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
